NeuroBo Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

MetaVia

28/03/2024 21:02

* NeuroBo Pharmaceuticals Inc  NRBO.OQ  reported a quarterly
adjusted loss of $2.28​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of $-14.56.  The mean expectation of
two analysts for the quarter was for a loss of 78 cents per
share. Wall Street expected results to range from -84 cents
to -73 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * NeuroBo Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $2.28​.
    * The company reported a quarterly loss of $5.31 million.
    * NeuroBo Pharmaceuticals Inc shares had risen by 17.4% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 1.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 1 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for NeuroBo
Pharmaceuticals Inc is $36.50 

This summary was machine generated from LSEG data March 28 at
09:02 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.78          -2.28          Missed
 Sep. 30 2023      -0.86          -0.72          Beat
 Jun. 30 2023      -1.01          -0.16          Beat
 Mar. 31 2023      -5.04          -0.77          Beat